ISABL INC.

Medtech · Private

Precision medicine platform that processes cancer whole genome and transcriptome sequencing data to generate clinically actionable diagnostic reports for pediatric and rare cancer patients

Grants
$2.0M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform$1,041,487
Federal grantDepartment of Health and Human Services · Phase II · Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform$991,890
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1878SILICON AUDIO, LLC——
1879BIODYNAMIK—$1.5M
1880SONAMED TECHNOLOGIES, LLC——
1881ISABL INC.——
1882DIGITOUCH HEALTH LLC——
1883NEUROTRAINER INC——
1884Niche Biomedical, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.